Metamizol Pensa Pharma

Metamizole, the active ingredient in Metamizol Pensa Pharma, is a pyrazolone‑class non‑opioid analgesic presented as an oral formulation for systemic use. It is employed to relieve mild to moderate pain, manage postoperative discomfort, reduce fever, and alleviate colic in adult patients.

GNH USA supplies Metamizol Pensa Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union pharmacopeial specifications and is manufactured under GMP conditions for consistent purity and potency globally.

Metamizole is a pyrazolone analgesic used to manage pain and fever.

Mild to moderate pain: Provides effective analgesia for acute or chronic pain conditions, improving patient comfort. Post‑operative pain: Reduces surgical site discomfort and facilitates early mobilization after procedures. Fever: Lowers elevated body temperature by acting on central thermoregulatory pathways. Colic: Alleviates visceral pain associated with gastrointestinal or biliary colic episodes.

Metamizole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: Gastrointestinal upset occurring shortly after dosing. - Dizziness or light‑headedness: Transient sensation of imbalance. - Hypotension: Mild drop in blood pressure, especially with rapid administration. - Rash or mild skin irritation: Localized erythema or itching. - Headache: Tension‑type discomfort. - Diarrhoea: Loose stools in some patients.

Serious or Rare Side Effects: - Agranulocytosis: Severe reduction in white blood cells, requiring immediate medical attention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: Life‑threatening skin reactions. - Anaphylactic shock: Rapid onset of severe allergic response. - Hepatic dysfunction: Elevated liver enzymes indicating liver injury. - Renal impairment: Decreased kidney function, especially in predisposed individuals. - Blood dyscrasias: Unusual bleeding or clotting abnormalities.

Careful assessment and monitoring are advised when using Metamizole. - Assess renal function: Adjust use in patients with severe renal impairment. - Monitor blood counts: Watch for early signs of agranulocytosis. - Avoid in known hypersensitivity: Discontinue if allergic reactions occur. - Use caution in hepatic disease: Consider liver function before initiation. - Pregnancy and lactation: Safety not established; weigh risks and benefits. - Store at ambient temperature: Keep in the original container, protect from moisture and direct sunlight.

Metamizole can interact with other medicines, requiring attention to potential risks.

Major Interactions (Avoid): - Myelotoxic agents (e.g., chemotherapy): Combined use may markedly increase risk of agranulocytosis. - Drugs lowering seizure threshold: May heighten seizure risk when used together.

Moderate Interactions (Monitor Closely): - NSAIDs: Additive gastrointestinal irritation and bleeding risk. - Cimetidine or other H2 blockers: May raise plasma levels of Metamizole. - Alcohol: Can enhance central nervous system depression. - Anticoagulants (e.g., warfarin): Potential for increased bleeding tendency. - Diuretics: May potentiate hypotensive effects.